2018-12: Observation of treatment patterns with Lucentis® (Ranibizumab) in real-life conditions in all approved indications
The Lucentis® product posologies of the European Union and Switzerland recommend the (re-) treatment of patients based on different disease activity criteria (change of visual acuity, retinal morphology) and different monitoring and/or treatment intervals. To date, no data regarding the different treatment regimens of Lucentis® patients in routine clinical practice and no up-to-date comparison between various European countries is available. This observational study is conducted to describe the utilization and effectiveness of Lucentis® in patients treated according to local routine clinical practice in all approved indications according to the local product posology. In addition, the results of this study from the different European countries will be compared with each other.